"Active surveillance is an innovation because it's truly a departure from the idea that all prostate cancers or cancer, in general, needs to be treated," says Kara L. Watts, MD.
In this installment in Urology Times®' 50th Anniversary Innovation Celebration series, Kara L. Watts, MD, discusses the emergence and increasing uptake of active surveillance as a management strategy for men with prostate cancer. Watts, a member of the Urology Times® Editorial Council, is an assistant professor of urology at Montefiore Medical Center, Bronx, New York.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.